Recent therapeutic advances in hematological malignancies: the role of targeted therapies in lymphoma.
Schmitz
N
N
Department of Haematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology / Q000532:radiotherapy / Q000628:therapy*; D016499:Radioimmunotherapy; D000069283:Rituximab; D015021:Yttrium Radioisotopes / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000922:Immunotoxins; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan